In this interview, Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, shares insights into the real-world evidence for C3 inhibition, which can block both intravascular and extravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). Global real-world data has demonstrated the efficacy and safety of C3 inhibitors, paving the way for new upstream complement inhibitors to be used in the treatment of PNH. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть